Crinetics Pharmaceuticals Stock Gross Profit

CRNX Stock

USD 56.09 0.03 0.05%

Crinetics Pharmaceuticals fundamentals help investors to digest information that contributes to Crinetics Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Crinetics Stock. The fundamental analysis module provides a way to measure Crinetics Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crinetics Pharmaceuticals stock.

	Last Reported	Projected for Next Year
Gross Profit	4 M	4.2 M
Gross Profit Margin	0.81	0.85

Gross Profit is likely to rise to about 4.2 M in 2024. Gross Profit Margin is likely to rise to 0.85 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Crinetics Pharmaceuticals Company Gross Profit Analysis

Crinetics Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Crinetics Pharmaceuticals Gross Profit

(125.49 M)

Most of Crinetics Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crinetics Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Crinetics Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Crinetics Pharmaceuticals is extremely important. It helps to project a fair market value of Crinetics Stock properly, considering its historical fundamentals such as Gross Profit. Since Crinetics Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crinetics Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crinetics Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue
Total Assets		0.5	0.95	-0.17	-0.98	0.78	-0.81	0.95	-0.81	0.83	0.86	-0.81	1.0	0.94	0.98	0.72	1.0	1.0	0.9	-0.79	0.98	0.83
Total Stockholder Equity	0.5		0.24	0.48	-0.47	0.06	-0.83	0.73	-0.83	0.14	0.8	-0.83	0.47	0.74	0.48	0.02	0.45	0.46	0.7	-0.07	0.48	0.44
Net Tangible Assets	0.95	0.24		-0.39	-0.93	0.84	-0.63	0.82	-0.63	0.92	0.67	-0.63	0.97	0.81	0.93	0.83	0.97	0.97	0.75	-0.87	0.93	0.75
Net Debt	-0.17	0.48	-0.39		0.09	-0.22	-0.23	0.07	-0.23	-0.41	0.27	-0.23	-0.2	0.07	-0.14	-0.43	-0.23	-0.21	0.24	0.44	-0.14	0.26
Retained Earnings	-0.98	-0.47	-0.93	0.09		-0.81	0.78	-0.93	0.78	-0.77	-0.88	0.78	-0.98	-0.92	-0.99	-0.67	-0.97	-0.98	-0.92	0.8	-0.99	-0.9
Accounts Payable	0.78	0.06	0.84	-0.22	-0.81		-0.39	0.65	-0.39	0.86	0.51	-0.39	0.79	0.65	0.8	0.9	0.8	0.79	0.59	-0.92	0.8	0.72
Long Term Debt	-0.81	-0.83	-0.63	-0.23	0.78	-0.39		-0.92	1.0	-0.49	-0.93	1.0	-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Net Receivables	0.95	0.73	0.82	0.07	-0.93	0.65	-0.92		-0.92	0.71	0.95	-0.92	0.94	1.0	0.93	0.59	0.93	0.94	0.94	-0.66	0.93	0.82
Long Term Debt Total	-0.81	-0.83	-0.63	-0.23	0.78	-0.39	1.0	-0.92		-0.49	-0.93	1.0	-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Capital Surpluse	0.83	0.14	0.92	-0.41	-0.77	0.86	-0.49	0.71	-0.49		0.48	-0.49	0.85	0.7	0.77	0.97	0.87	0.85	0.54	-0.88	0.77	0.57
Total Liab	0.86	0.8	0.67	0.27	-0.88	0.51	-0.93	0.95	-0.93	0.48		-0.93	0.84	0.96	0.87	0.35	0.81	0.83	0.97	-0.49	0.87	0.85
Short Long Term Debt	-0.81	-0.83	-0.63	-0.23	0.78	-0.39	1.0	-0.92	1.0	-0.49	-0.93		-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Total Current Assets	1.0	0.47	0.97	-0.2	-0.98	0.79	-0.79	0.94	-0.79	0.85	0.84	-0.79		0.93	0.98	0.74	1.0	1.0	0.88	-0.81	0.98	0.83
Short Term Debt	0.94	0.74	0.81	0.07	-0.92	0.65	-0.91	1.0	-0.91	0.7	0.96	-0.91	0.93		0.92	0.58	0.92	0.93	0.93	-0.65	0.92	0.81
Common Stock	0.98	0.48	0.93	-0.14	-0.99	0.8	-0.8	0.93	-0.8	0.77	0.87	-0.8	0.98	0.92		0.68	0.97	0.98	0.91	-0.82	1.0	0.87
Property Plant Equipment	0.72	0.02	0.83	-0.43	-0.67	0.9	-0.32	0.59	-0.32	0.97	0.35	-0.32	0.74	0.58	0.68		0.76	0.74	0.4	-0.9	0.68	0.47
Net Invested Capital	1.0	0.45	0.97	-0.23	-0.97	0.8	-0.77	0.93	-0.77	0.87	0.81	-0.77	1.0	0.92	0.97	0.76		1.0	0.86	-0.82	0.97	0.81
Net Working Capital	1.0	0.46	0.97	-0.21	-0.98	0.79	-0.78	0.94	-0.78	0.85	0.83	-0.78	1.0	0.93	0.98	0.74	1.0		0.88	-0.81	0.98	0.82
Short Term Investments	0.9	0.7	0.75	0.24	-0.92	0.59	-0.89	0.94	-0.89	0.54	0.97	-0.89	0.88	0.93	0.91	0.4	0.86	0.88		-0.53	0.91	0.93
Deferred Long Term Liab	-0.79	-0.07	-0.87	0.44	0.8	-0.92	0.45	-0.66	0.45	-0.88	-0.49	0.45	-0.81	-0.65	-0.82	-0.9	-0.82	-0.81	-0.53		-0.82	-0.58
Capital Stock	0.98	0.48	0.93	-0.14	-0.99	0.8	-0.8	0.93	-0.8	0.77	0.87	-0.8	0.98	0.92	1.0	0.68	0.97	0.98	0.91	-0.82		0.87
Current Deferred Revenue	0.83	0.44	0.75	0.26	-0.9	0.72	-0.73	0.82	-0.73	0.57	0.85	-0.73	0.83	0.81	0.87	0.47	0.81	0.82	0.93	-0.58	0.87

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Crinetics Pharmaceuticals

Gross Profit Over Time

According to the company disclosure, Crinetics Pharmaceuticals reported (125.49 Million) of gross profit. This is 105.59% lower than that of the Biotechnology sector and 113.2% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.46% higher than that of the company.

Crinetics Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crinetics Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crinetics Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Crinetics Pharmaceuticals by comparing valuation metrics of similar companies.

Crinetics Pharmaceuticals is currently under evaluation in gross profit category among its peers.

Crinetics Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crinetics Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crinetics Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Crinetics Fundamentals

	Return On Equity	-0.4
	Return On Asset	-0.24
	Operating Margin	(295.25) %
	Current Valuation	4.39 B
	Shares Outstanding	92.74 M
	Shares Owned By Insiders	1.79 %
	Shares Owned By Institutions	94.68 %
	Number Of Shares Shorted	6.94 M
	Price To Earning	(12.03) X
	Price To Book	6.24 X
	Price To Sales	5,006 X
	Revenue	4.01 M
	Gross Profit	(125.49 M)
	EBITDA	(221.51 M)
	Net Income	(214.53 M)
	Cash And Equivalents	408.51 M
	Cash Per Share	7.60 X
	Total Debt	51.73 M
	Debt To Equity	0.01 %
	Current Ratio	15.94 X
	Book Value Per Share	10.30 X
	Cash Flow From Operations	(166.31 M)
	Short Ratio	8.47 X
	Earnings Per Share	(3.70) X
	Target Price	73.29
	Number Of Employees	290
	Beta	0.62
	Market Capitalization	5.2 B
	Total Asset	635.35 M
	Retained Earnings	(653.7 M)
	Working Capital	530.21 M
	Current Asset	44.96 M
	Current Liabilities	2.41 M
	Net Asset	635.35 M

About Crinetics Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Crinetics Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crinetics Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crinetics Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC